Stephanie Davis
Stock Analyst at Barclays
(0.58)
# 4,165
Out of 5,131 analysts
94
Total ratings
31.82%
Success rate
-109.84%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Equal-Weight | $190 → $195 | $174.44 | +11.79% | 7 | Oct 22, 2025 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $34.50 | +30.43% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $13.16 | -62.01% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $43.79 | +71.27% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $7.40 | -5.41% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $2.80 | +114.29% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $4.17 | +355.64% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $335.69 | -13.61% | 2 | Nov 7, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $201.11 | -33.87% | 2 | Nov 4, 2024 | |
| OMCL Omnicell | Maintains: Equal-Weight | $39 → $58 | $50.74 | +14.31% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $4.02 | -25.37% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $251.81 | -1.12% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $17.23 | +68.31% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $7.46 | +355.76% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $26.99 | +25.97% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $240.12 | -2.97% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $2.48 | +585.48% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $94.15 | -19.28% | 5 | Jun 7, 2022 |
Quest Diagnostics
Oct 22, 2025
Maintains: Equal-Weight
Price Target: $190 → $195
Current: $174.44
Upside: +11.79%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $34.50
Upside: +30.43%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $13.16
Upside: -62.01%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $43.79
Upside: +71.27%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $7.40
Upside: -5.41%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $2.80
Upside: +114.29%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $4.17
Upside: +355.64%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $335.69
Upside: -13.61%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $201.11
Upside: -33.87%
Omnicell
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $50.74
Upside: +14.31%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $4.02
Upside: -25.37%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $251.81
Upside: -1.12%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $17.23
Upside: +68.31%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $7.46
Upside: +355.76%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $26.99
Upside: +25.97%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $240.12
Upside: -2.97%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $2.48
Upside: +585.48%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $94.15
Upside: -19.28%